+41.0%
CLS vs MRNA
+485.7%
-444.7%
-41.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +6.6% | +5.4% | +1.2% | +6.5% |
| 7D | +10.9% | -1.1% | +12.0% | +11.0% |
| 30D | +2.1% | +126.1% | -124.0% | +0.7% |
| 3M | -10.2% | +190.0% | -200.2% | -17.1% |
| 6M | +30.4% | +157.2% | -126.8% | +23.0% |
| YTD | +17.2% | +388.2% | -371.0% | -8.2% |
| 1Y | +41.0% | +467.0% | -426.0% | +6.5% |
| All | +41.0% | +485.7% | -444.7% | +6.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling